(HIMSS Booth #6045) -- 2bPrecise, LLC today announced the general availability of its EHR-agnostic, cloud-based precision medicine platform. The 2bPrecise solution captures and securely stores genomic data, which it harmonizes with research knowledge and clinical information. It then pushes the resulting insights to the point of care, enabling the clinician to take action.

2bPrecise is now giving physicians across the country the ability to practically apply precision medicine to diagnose and treat their patients. National Institutes of Health and Holston Medical Group are currently participating in early adopter programs. By delivering understandable and actionable genomic insights into physicians’ existing clinical workflows, the platform enables informed decision-making in an effort to improve outcomes and reduce costs.

“As the pace of genomic discovery continues to accelerate, the mountain of genetic data – separated in clinical, lab or other systems – continues to grow,” said Assaf Halevy, founder and CEO of 2bPrecise. “For patients to benefit from this expanding body of knowledge, we need to get the relevant insights into the hands of treating providers without disrupting their existing workflows. 2bPrecise is the last-mile solution that closes this information gap, empowering physicians to provide the most precise care.”

A wholly owned subsidiary of Allscripts Healthcare Inc., 2bPrecise’s vendor-neutral solution is uniquely positioned for success. “Allscripts prides itself on its reputation for investing in open platforms driven by entrepreneurial leaders, with the goal of helping providers regardless of their current HCIT platform,” said Paul Black, CEO of Allscripts. “Our support of 2bPrecise is no exception, and we are committed to helping cultivate its innovative approach to precision medicine; making genomic insights actionable and accessible for providers.” 

Key components of the 2bPrecise platform include:

  • A genomic repository that semantically tags information from a range of clinical and genomic sources, and that extracts meaningful insights for providers and researchers.
  • A robust knowledge hub that assembles information from a wide range of sources, enabling providers to access the most current clinically validated information available.
  • A point of care solution that delivers actionable genomic intelligence directly into the existing workflow.
  • A research-ready framework for closed-loop research-to-care translations that can establish the foundation for future scientific discovery. 

To learn more, visit 2bPrecise at HIMSS booth #6045.

About 2bPrecise 2bPrecise harnesses the power of genomics and precision medicine in an effort to precisely predict and efficiently treat each individual patient. 2bPrecise’s EHR-agnostic, cloud-based platform captures and stores genomic data and harmonizes it with research knowledge and clinical information. The resulting actionable insights are then pushed into a provider’s existing clinical workflow to facilitate decision-making at the point of care. Learn more at www.2bPrecisehealth.com.

About AllscriptsAllscripts (NASDAQ:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

Media Contact:

Danielle Johns
Aria Marketing for 2bPrecise
djohns@ariamarketing.com
617-332-9999 x241

Concetta Rasiarmos
Allscripts Public Relations
concetta.rasiarmos@allscripts.com
630-740-3152

Investors:

Seth Frank
Allscripts Vice President of Investor Relations
312-506-1213
seth.frank@allscripts.com
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Veradigm Charts.
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Veradigm Charts.